Oculogyric crises: Etiology, pathophysiology and therapeutic approaches

Parkinsonism and Related Disorders

Volumn 36, Issue , 2017, Pages 3-9

  Barow, Ewgenia ^a   Schneider, Susanne A ^b   Bhatia, Kailash P ^c   Ganos, Christos ^a,c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Acute dystonic reaction; Drug induced dystonia; Dystonia; Oculogyric crisis

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BENZATROPINE; BIPERIDEN; CARBAMAZEPINE; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; EDROPHONIUM CHLORIDE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HALOPERIDOL; ISOTRETINOIN; LEVODOPA; LITHIUM; METOCLOPRAMIDE; NEUROLEPTIC AGENT; NIFEDIPINE; PENTAZOCINE; PHENCYCLIDINE; SALICYLIC ACID DERIVATIVE; SEPIAPTERIN REDUCTASE; TETRABENAZINE; TYROSINE 3 MONOOXYGENASE;

BINSWANGER ENCEPHALOPATHY; BLEPHAROSPASM; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPIDEMIC ENCEPHALITIS; EPILEPSY; HERPES SIMPLEX ENCEPHALITIS; HUMAN; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROSYPHILIS; OCULOGYRIC CRISIS; ORGANOPHOSPHATE POISONING; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; RETT SYNDROME; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; DYSKINESIA; DYSTONIA; EYE MOVEMENT DISORDER;

ANTIDEPRESSIVE AGENTS; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; DYSTONIA; HUMANS; OCULAR MOTILITY DISORDERS;

EID: 85007545496     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.11.012     Document Type: Review

References (128)

1. [1] FitzGerald, P.M., Jankovic, J., Tardive oculogyric crises. Neurology 39 (1989), 1434–1437.
2. [2] Berger, J.R., Vilensky, J.A., Encephalitis lethargica (von Economo's encephalitis). Handb. Clin. Neurol. 123 (2014), 745–761.
3. [3] Ayd, F.J. Jr., A survey of drug-induced extrapyramidal reactions. JAMA 175 (1961), 1054–1060.
4. [4] Kurian, M.A., Gissen, P., Smith, M., Heales, S. Jr., Clayton, P.T., The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 10 (2011), 721–733.
5. [5] Lee, M.S., Kim, Y.D., Lyoo, C.H., Oculogyric crisis as an initial manifestation of Wilson's disease. Neurology 52 (1999), 1714–1715.
6. [6] Lee, J.H., Lyoo, C.H., Lee, J.G., Lee, M.S., Oculogyric crisis associated with disulfiram-induced pallidonigral lesion. J. Mov. Disord. 2 (2009), 48–49.
7. [7] Matsumura, K., Sakuta, M., Oculogyric crisis in acute herpetic brainstem encephalitis. J. Neurol. Neurosurg. Psychiatry 50 (1987), 365–366.
8. [8] Sachdev, P., Tardive and chronically recurrent oculogyric crises. Mov. Disord. 8 (1993), 93–97.
9. [9] Schneider, S.A., Udani, V., Sankhla, C.S., Bhatia, K.P., Recurrent acute dystonic reaction and oculogyric crisis despite withdrawal of dopamine receptor blocking drugs. Mov. Disord. 24 (2009), 1226–1229.
10. [10] Gardner, D.M., Abidi, S., Ursuliak, Z., Morrison, J., Teehan, M.D., Tibbo, P.G., Incidence of oculogyric crisis and long-term outcomes with second-generation antipsychotics in a first-episode psychosis program. J. Clin. Psychopharmacol. 35 (2015), 715–718.
11. [11] Abe, K., Psychiatric symptoms associated with oculogyric crisis: a review of literature for the characterization of antipsychotic-induced episodes. World J. Biol. Psychiatry 7 (2006), 70–74.
12. [12] Leigh, R.J., Foley, J.M., Remler, B.F., Civil, R.H., Oculogyric crisis: a syndrome of thought disorder and ocular deviation. Ann. Neurol. 22 (1987), 13–17.
13. [13] Thornton, A., McKenna, P.J., Acute dystonic reactions complicated by psychotic phenomena. Br. J. Psychiatry 164 (1994), 115–118.
14. [14] Sacks, O.W., Kohl, M., L-dopa and oculogyric crises. Lancet 2 (1970), 215–216.
15. [15] Wyllie, E., Luders, H., Morris, H.H., Lesser, R.P., Dinner, D.S., The lateralizing significance of versive head and eye movements during epileptic seizures. Neurology 36 (1986), 606–611.
16. [16] Jankovic, J., Stone, L., Dystonic tics in patients with Tourette's syndrome. Mov. Disord. 6 (1991), 248–252.
17. [17] Salmina, C., Taddeo, I., Falesi, M., Weber, P., Bianchetti, M.G., Ramelli, G.P., Paroxysmal tonic upgaze in normal children: a case series and a review of the literature. Eur. J. Paediatr. Neurol. 16 (2012), 683–687.
18. [18] Sachdev, P.S., Neuroleptic-induced movement disorders: an overview. Psychiatr. Clin. North Am. 28 (2005), 255–274 (x).
19. [19] Keepers, G.A., Casey, D.E., Prediction of neuroleptic-induced dystonia. J. Clin. Psychopharmacol. 7 (1987), 342–345.
20. [20] Swett, C. Jr., Drug-induced dystonia. Am. J. Psychiatry 132 (1975), 532–534.
21. [21] Aguilar, E.J., Keshavan, M.S., Martinez-Quiles, M.D., Hernandez, J., Gomez-Beneyto, M., Schooler, N.R., Predictors of acute dystonia in first-episode psychotic patients. Am. J. Psychiatry 151 (1994), 1819–1821.
22. [22] Chakos, M.H., Mayerhoff, D.I., Loebel, A.D., Alvir, J.M., Lieberman, J.A., Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol. Bull. 28 (1992), 81–86.
23. [23] Koban, Y., Ekinci, M., Cagatay, H.H., Yazar, Z., Oculogyric crisis in a patient taking metoclopramide. Clin. Ophthalmol. 8 (2014), 567–569.
24. [24] Edwards, M., Koo, M.W., Tse, R.K., Oculogyric crisis after metoclopramide therapy. Optom. Vis. Sci. 66 (1989), 179–180.
25. [25] Lou, E., Abou-Zeid, N., A case of metoclopramide-induced oculogyric crisis in a 16-year-old girl with cystic fibrosis. South Med. J. 99 (2006), 1290–1291.
26. [26] Karagoz, G., Kadanali, A., Dede, B., Anadol, U., Yucel, M., Bektasoglu, M.F., Metoclopramide-induced acute dystonic reaction: a case report. Eurasian J. Med. 45 (2013), 58–59.
27. [27] Arumugam, J., Vijayalakshmi, A.M., Metoclopramide-induced oculogyric crisis presenting as encephalitis in a young girl. Indian J. Pharmacol. 44 (2012), 266–267.
28. [28] Harries, J.R., Oculogyric crises due to phenothiazines. Br. Med. J., 3, 1967, 241.
29. [29] Kim, W., Lee, K.S., Kim, Y.I., Kim, J.S., Acute oculogyric crisis in a patient taking clebopride. Intern Med. 47 (2008), 551–552.
30. [30] Macachor, J.D., Kurniawan, M., Loganathan, S.B., Ondansetron-induced oculogyric crisis. Eur. J. Anaesthesiol. 31 (2014), 712–713.
31. [31] Dingwall, A.E., Oculogyric crisis after day case anaesthesia. Anaesthesia, 42, 1987, 565.
32. [32] Berchou, R.C., Rodin, E.A., Carbamazepine-induced oculogyric crisis. Arch. Neurol. 36 (1979), 522–523.
33. [33] Gorman, M., Barkley, G.L., Oculogyric crisis induced by carbamazepine. Epilepsia 36 (1995), 1158–1160.
34. [34] AlAzwary, N.H., Muayqil, T., Siddiqi, Z.A., Ahmed, S.N., Oculogyric crisis masquerading as ventriculoperitoneal shunt dysfunction. J. Neurosurg. 109 (2008), 944–945.
35. [35] Arnstein, E., Oculogyric crisis: a distinct toxic effect of carbamazepine. J. Child. Neurol. 1 (1986), 289–290.
36. [36] Veerapandiyan, A., Gallentine, W.B., Winchester, S.A., Baker, J., Kansagra, S.M., Mikati, M.A., Oculogyric crises secondary to lamotrigine overdosage. Epilepsia 52 (2011), e4–6.
37. [37] Reeves, A.L., So, E.L., Sharbrough, F.W., Krahn, L.E., Movement disorders associated with the use of gabapentin. Epilepsia 37 (1996), 988–990.
38. [38] Gatzonis, S.D., Georgaculias, N., Singounas, E., Jenkins, A., Stamboulis, E., Siafakas, A., Elimination of oxcarbazepine-induced oculogyric crisis following vagus nerve stimulation. Neurology 52 (1999), 1918–1919.
39. [39] Chechani, V., Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. Crit. Care Med. 30 (2002), 473–476.
40. [40] Tikka, S.K., Garg, S., Das, B., Fluvoxamine induced oculogyric dystonia and manic switch in a patient with obsessive compulsive disorder. Indian J. Pharmacol. 45 (2013), 532–533.
41. [41] Patel, O.P., Simon, M.R., Oculogyric dystonic reaction to escitalopram with features of anaphylaxis including response to epinephrine. Int. Arch. Allergy Immunol. 140 (2006), 27–29.
42. [42] Tahiroglu, A.Y., Avci, A., Imipramine, methylphenidate and valproic acid-related EPS in a child: a case report. Int. J. Neuropsychopharmacol. 10 (2007), 705–707.
43. [43] Fraunfelder, F.W., Fraunfelder, F.T., Oculogyric crisis in patients taking cetirizine. Am. J. Ophthalmol. 137 (2004), 355–357.
44. [44] Hsieh, B.H., Deng, J.F., Ger, J., Tsai, W.J., Acetylcholinesterase inhibition and the extrapyramidal syndrome: a review of the neurotoxicity of organophosphate. Neurotoxicology 22 (2001), 423–427.
45. [45] Janik, P., Figura, M., Tetrabenazine-induced oculogyric crisis - a rare complication in the treatment of Gilles de la Tourette syndrome. Neuropsychiatr. Dis. Treat. 12 (2016), 497–499.
46. [46] Jankovic, J., Glaze, D.G., Frost, J.D. Jr., Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology 34 (1984), 688–692.
47. [47] LeWitt, P.A., Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease. Mov. Disord. 13 (1998), 731–734.
48. [48] Sandyk, R., Oculogyric crisis induced by lithium carbonate. Eur. Neurol. 23 (1984), 92–94.
49. [49] Nucci, P., Brancato, R., Oculogyric crisis after the Tensilon test. Graefes Arch. Clin. Exp. Ophthalmol. 228 (1990), 384–385.
50. [50] Bayram, E., Bayram, M.T., Hiz, S., Turkmen, M., Cefixime-induced oculogyric crisis. Pediatr. Emerg. Care 28 (2012), 55–56.
51. [51] Burstein, A.H., Fullerton, T., Oculogyric crisis possibly related to pentazocine. Ann. Pharmacother. 27 (1993), 874–876.
52. [52] Singh, I., Prolonged oculogyric crisis on addition of nifedipine to neuroleptic medication regime. Br. J. Psychiatry 150 (1987), 127–128.
53. [53] Bigby, M., Stern, R.S., Adverse reactions to isotretinoin. A report from the adverse drug reaction reporting system. J. Am. Acad. Dermatol. 18 (1988), 543–552.
54. [54] Tahir, H., Daruwalla, V., Phencyclidine induced oculogyric crisis responding well to conventional treatment. Case Rep. Emerg. Med., 2015, 2015, 506301.
55. [55] Chiaretti, A., Schembri Wismayer, D., Tortorolo, L., Piastra, M., Polidori, G., Salicylate intoxication using a skin ointment. Acta Paediatr. 86 (1997), 330–331.
56. [56] Mendhekar, D.N., Duggal, H.S., Isolated oculogyric crisis on clozapine discontinuation. J. Neuropsychiatry Clin. Neurosci. 18 (2006), 424–425.
57. [57] Kis, B., Hedrich, K., Kann, M., et al. Oculogyric dystonic states in early-onset parkinsonism with basal ganglia calcifications. Neurology, 65, 2005, 761.
58. [58] Furuta, N., Furuta, M., Makioka, K., Fujita, Y., Okamoto, K., Parkinson's disease presenting with oculogyric crisis in the off period. Intern Med. 53 (2014), 793–795.
59. [59] Brun, L., Ngu, L.H., Keng, W.T., et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 75 (2010), 64–71.
60. [60] Manegold, C., Hoffmann, G.F., Degen, I., et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J. Inherit. Metab. Dis. 32 (2009), 371–380.
61. [61] Swoboda, K.J., Saul, J.P., McKenna, C.E., Speller, N.B., Hyland, K., Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann. Neurol. 54:Suppl 6 (2003), S49–S55.
62. [62] Friedman, J., Roze, E., Abdenur, J.E., et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann. Neurol. 71 (2012), 520–530.
63. [63] Koht, J., Rengmark, A., Opladen, T., et al. Clinical and genetic studies in a family with a novel mutation in the sepiapterin reductase gene. Acta Neurol. Scand. Suppl., 2014, 7–12.
64. [64] Clot, F., Grabli, D., Cazeneuve, C., et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain 132 (2009), 1753–1763.
65. [65] Neville, B.G., Parascandalo, R., Farrugia, R., Felice, A., Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain 128 (2005), 2291–2296.
66. [66] Brautigam, C., Steenbergen-Spanjers, G.C., Hoffmann, G.F., et al. Biochemical and molecular genetic characteristics of the severe form of tyrosine hydroxylase deficiency. Clin. Chem. 45 (1999), 2073–2078.
67. [67] Grattan-Smith, P.J., Wevers, R.A., Steenbergen-Spanjers, G.C., Fung, V.S., Earl, J., Wilcken, B., Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy. Mov. Disord. 17 (2002), 354–359.
68. [68] Zafeiriou, D.I., Willemsen, M.A., Verbeek, M.M., Vargiami, E., Ververi, A., Wevers, R., Tyrosine hydroxylase deficiency with severe clinical course. Mol. Genet. Metab. 97 (2009), 18–20.
69. [69] Pons, R., Serrano, M., Ormazabal, A., et al. Tyrosine hydroxylase deficiency in three Greek patients with a common ancestral mutation. Mov. Disord. 25 (2010), 1086–1090.
70. [70] Al-Muslamani, A.M., Ali, F., Mahmood, F., A new tyrosine hydroxylase genotype with orofacial dyskinaesia. Sultan Qaboos Univ. Med. J. 14 (2014), e397–400.
71. [71] Horvath, G.A., Stockler-Ipsiroglu, S.G., Salvarinova-Zivkovic, R., et al. Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: evidence of a phenotypic continuum between dominant and recessive forms. Mol. Genet. Metab. 94 (2008), 127–131.
72. [72] Lamberti, P., de Mari, M., Iliceto, G., Caldarola, M., Serlenga, L., Effect of L-dopa on oculogyric crises in a case of dopa-responsive dystonia. Mov. Disord. 8 (1993), 236–237.
73. [73] FitzGerald, P.M., Jankovic, J., Percy, A.K., Rett syndrome and associated movement disorders. Mov. Disord. 5 (1990), 195–202.
74. [74] Jacobsen, J.C., Wilson, C., Cunningham, V., et al. Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder. J. Inherit. Metab. Dis. 39 (2016), 305–308.
75. [75] Rilstone, J.J., Alkhater, R.A., Minassian, B.A., Brain dopamine-serotonin vesicular transport disease and its treatment. N. Engl. J. Med. 368 (2013), 543–550.
76. [76] Williams, D.R., Hadeed, A., al-Din, A.S., Wreikat, A.L., Lees, A.J., Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov. Disord. 20 (2005), 1264–1271.
77. [77] Yang, X., Xu, Y., Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review. Biomed. Res. Int., 2014, 2014, 371256.
78. [78] Lai, S.C., Jung, S.M., Grattan-Smith, P., et al. Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. Mov. Disord. 25 (2010), 1274–1279.
79. [79] Parker, J.C. Jr., Dyer, M.L., Paulsen, W.A., Neuronal intranuclear hyaline inclusion disease associated with premature coronary atherosclerosis. J. Clin. Neuroophthalmol. 7 (1987), 244–249.
80. [80] Virmani, T., Thenganatt, M.A., Goldman, J.S., Kubisch, C., Greene, P.E., Alcalay, R.N., Oculogyric crises induced by levodopa in PLA2G6 parkinsonism-dystonia. Park. Relat. Disord. 20 (2014), 245–247.
81. [81] Zupanc, M.L., Chun, R.W., Gilbert-Barness, E.F., Osmiophilic deposits in cytosomes in Hallervorden-Spatz syndrome. Pediatr. Neurol. 6 (1990), 349–352.
82. [82] Ohba, C., Shiina, M., Tohyama, J., et al. GRIN1 mutations cause encephalopathy with infantile-onset epilepsy, and hyperkinetic and stereotyped movement disorders. Epilepsia 56 (2015), 841–848.
83. [83] Mercimek-Mahmutoglu, S., van der Knaap, M.S., Baric, I., Prayer, D., Stoeckler-Ipsiroglu, S., Hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). Report of a new case. Neuropediatrics 36 (2005), 223–226.
84. [84] Oblak, A.L., Hagen, M.C., Sweadner, K.J., et al. Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings. Acta Neuropathol. 128 (2014), 81–98.
85. [85] Chung, E.J., Hwang, J.H., Lee, M.J., et al. Expansion of the clinicopathological and mutational spectrum of Perry syndrome. Park. Relat. Disord. 20 (2014), 388–393.
86. [86] Uyama, E., Hirano, T., Ito, K., et al. Adult Chediak-Higashi syndrome presenting as parkinsonism and dementia. Acta Neurol. Scand. 89 (1994), 175–183.
87. [87] Urra, D.G., Campos, J., Garcia Ruiz, P., Varela de Seijas, E., Garcia de Yebenes, J., Movement disorders in ataxia-teleangiectasia: review of six patients. Neurology, 39(Suppl 1), 1989, 321.
88. [88] Hanagasi, H.A., Lees, A., Johnson, J.O., Singleton, A., Emre, M., Smoking-responsive juvenile-onset parkinsonism. Mov. Disord. 22 (2007), 115–119.
89. [89] Cheney, G., Martins, S., Postencephalitic paroxysmal oculogyric crises: report of cases. Cal. West Med. 33 (1930), 724–728.
90. [90] Hoffman, H.L., Effect of benzedrine on the oculogyric crises of parkinsonism. Br. Med. J. 1 (1941), 816–818.
91. [91] Lieberman, A., Adolf hitler had post-encephalitic parkinsonism. Park. Relat. Disord. 2 (1996), 95–103.
92. [92] Onuaguluchi, G., Crises in post-encephalitic parkinsonism. Brain 84 (1961), 395–414.
93. [93] Clough, C.G., Plaitakis, A., Yahr, M.D., Oculogyric crises and parkinsonism. A case of recent onset. Arch. Neurol. 40 (1983), 36–37.
94. [94] Dale, R.C., Webster, R., Gill, D., Contemporary encephalitis lethargica presenting with agitated catatonia, stereotypy, and dystonia-parkinsonism. Mov. Disord. 22 (2007), 2281–2284.
95. [95] Sridam, N., Phanthumchinda, K., Encephalitis lethargica like illness: case report and literature review. J. Med. Assoc. Thai 89 (2006), 1521–1527.
96. [96] Kalita, J., Misra, U.K., Markedly severe dystonia in Japanese encephalitis. Mov. Disord. 15 (2000), 1168–1172.
97. [97] Wycis, H.T., Spiegel, E.A., Parkinsonism with oculogyric crises; stimulation and partial elimination of periaqueductal grey and mesencephalic tegmentum (tegmentotomy). Confin. Neurol. 18 (1958), 385–393.
98. [98] Shimizu, N., Mizuno, M., Oculomotor characteristics of parkinsonism in comparison with those of cerebellar ataxia. J. Neural Transm. Suppl. 19 (1983), 233–242.
99. [99] Scarmeas, N., Eidelberg, D., Frucht, S.J., Oculogyric-like crises in a 92-year-old woman with vascular Parkinsonism. Mov. Disord. 16 (2001), 353–355.
100. [100] Aramideh, M., Bour, L.J., Koelman, J.H., Speelman, J.D., Ongerboer de Visser, B.W., Abnormal eye movements in blepharospasm and involuntary levator palpebrae inhibition. Clinical and pathophysiological considerations. Brain 117:Pt 6 (1994), 1457–1474.
101. [101] Ferrara, J., Gupta, D., Foster, E., Garman, K., Stacy, M., Extraocular muscle dystonia due to acquired (non-Wilsonian) hepatocerebral degeneration. Mov. Disord. 23 (2008), 875–878.
102. [102] Baizabal-Carvallo, J.F., Jankovic, J., Functional (psychogenic) saccadic oscillations and oculogyric crises. Lancet Neurol., 15, 2016, 791.
103. [103] Della Marca, G., Frisullo, G., Vollono, C., et al. Oculogyric crisis in a midbrain lesion. Arch. Neurol. 68 (2011), 390–391.
104. [104] Heimburger, R.F., Positional oculogyric crises. Case report. J. Neurosurg. 69 (1988), 951–953.
105. [105] Liu, G.T., Carrazana, E.J., Macklis, J.D., Mikati, M.A., Delayed oculogyric crises associated with striatocapsular infarction. J. Clin. Neuroophthalmol. 11 (1991), 198–201.
106. [106] Schoser, B.G., Groden, C., Subacute onset of oculogyric crises and generalized dystonia following intranasal administration of heroin. Addiction 94 (1999), 431–434.
107. [107] Kim, J.S., Kim, H.K., Im, J.H., Lee, M.C., Oculogyric crisis and abnormal magnetic resonance imaging signals in bilateral lentiform nuclei. Mov. Disord. 11 (1996), 756–758.
108. [108] Ritter, M.J., Goodman, B.P., Sprung, J., Wijdicks, E.F., Ondansetron-induced multifocal encephalopathy. Mayo Clin. Proc. 78 (2003), 1150–1152.
109. [109] Antunes, N.L., Small, T.N., George, D., Boulad, F., Lis, E., Posterior leukoencephalopathy syndrome may not be reversible. Pediatr. Neurol. 20 (1999), 241–243.
110. [110] Duke-Elder, S., Scott, G.I., Ocular Deviations. System of Ophthalmology. 1971, Henry Kimpton, London.
111. [111] Henry, M.M., Jellinger, K.A., Postencephalitic Parkinsonism. 2003, ISN Neuropath Press, Los Angeles.
112. [112] Marsden, C.D., Jenner, P., The Pathophys of Extrapyramidal Side Effects of Neuroleptic Drugs. 1980.
113. [113] Chuhma, N., Mingote, S., Moore, H., Rayport, S., Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling. Neuron 81 (2014), 901–912.
114. [114] Kharkwal, G., Brami-Cherrier, K., Lizardi-Ortiz, J.E., et al. Parkinsonism driven by antipsychotics originates from dopaminergic control of striatal cholinergic interneurons. Neuron 91 (2016), 67–78.
115. [115] Teo, J.T., Edwards, M.J., Bhatia, K., Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov. Disord. 27 (2012), 1205–1215.
116. [116] Prisco, S., Esposito, E., Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area. Br. J. Pharmacol. 116 (1995), 1923–1931.
117. [117] Hansen, L., A critical review of akathisia, and its possible association with suicidal behaviour. Hum. Psychopharmacol. 16 (2001), 495–505.
118. [118] Dray, A., Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. J. Physiol. (Paris) 77 (1981), 393–403.
119. [119] Frucht, S.J., Treatment of movement disorder emergencies. Neurotherapeutics 11 (2014), 208–212.
120. [120] van Harten, P.N., Hoek, H.W., Kahn, R.S., Acute dystonia induced by drug treatment. BMJ 319 (1999), 623–626.
121. [121] Cortese, L., Pourcher-Bouchard, E., Williams, R., Assessment and management of antipsychotic-induced adverse events. Can. J. Psychiatry 43:Suppl 1 (1998), 15S–20S.
122. [122] Lee, A.S., Treatment of drug-induced dystonic reactions. JACEP 8 (1979), 453–457.
123. [123] Horiguchi, J., Inami, Y., Effect of clonazepam on neuroleptic-induced oculogyric crisis. Acta Psychiatr. Scand. 80 (1989), 521–523.
124. [124] Factor, S.A., Friedman, J.H., The emerging role of clozapine in the treatment of movement disorders. Mov. Disord. 12 (1997), 483–496.
125. [125] Spivak, B., Mester, R., Abesgaus, J., et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J. Clin. Psychiatry 58 (1997), 318–322.
126. [126] Chakraborty, R., Chatterjee, A., Clozapine-induced oculogyric crises. Ann. Pharmacother., 41, 2007, 1916.
127. [127] Uzun, O., Doruk, A., Tardive oculogyric crisis during treatment with clozapine: report of three cases. Clin. Drug Investig. 27 (2007), 861–864.
128. [128] Nebhinani, N., Avasthi, A., Modi, M., Oculogyric crisis with clozapine: a case report and review of similar case reports in the literature. Indian J. Psychol. Med. 37 (2015), 342–344.